Lumos Pharma, Inc.
(NASDAQ : NLNK)

( )
NLNK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.05%53.950.9%$1407.48m
JNJJohnson & Johnson 0.14%179.790.7%$1298.25m
BMYBristol-Myers Squibb Co. 0.01%77.601.0%$1212.32m
MRKMerck & Co., Inc. -0.21%92.130.7%$1164.62m
ABBVAbbVie, Inc. 0.13%150.751.9%$1101.69m
LLYEli Lilly & Co. 0.13%313.891.1%$968.54m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.14%142.980.0%$491.89m
AZNAstraZeneca Plc -0.70%66.231.0%$488.04m
NVSNovartis AG 0.01%91.270.2%$259.87m
GSKGlaxoSmithKline Plc -0.33%44.270.2%$256.72m
VERUVeru, Inc. 0.55%12.710.0%$255.11m
HZNPHorizon Therapeutics Plc 0.00%90.595.4%$196.03m
SGENSeagen Inc. 1.16%140.065.7%$187.81m
NVONovo Nordisk A/S -0.58%106.000.1%$181.83m
VTRSViatris, Inc. 0.58%12.080.0%$166.23m

Company Profile

Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Austin, TX.